Pola-R-CHP联合自体干细胞移植治疗未经治疗的伯基特淋巴瘤1例

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL
Yang Yang, Yuhong Ren, Jing Li, Peng Liu
{"title":"Pola-R-CHP联合自体干细胞移植治疗未经治疗的伯基特淋巴瘤1例","authors":"Yang Yang, Yuhong Ren, Jing Li, Peng Liu","doi":"10.12659/AJCR.948969","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND Burkitt lymphoma is an aggressive B-cell lymphoma curable with highly dose-intensive chemotherapy derived from pediatric leukemia regimens. However, the adverse event profile, including myelosuppression, infection, and multi-organ dysfunction, worsens with increasing age. This report describes the first case of an 56-year-old woman diagnosed with Burkitt lymphoma who was treated with upfront polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) followed by autologous stem cell transplantation consolidation. CASE REPORT An 56-year-old Asian female patient with reduced body weight and severe malnutrition and unfit for standard therapies had an aggravating onset of abdominal pain and constipation. Diagnosis of high-risk Burkitt lymphoma was made by pathological biopsy, with intermediate-sized mature malignant B cells that expressed CD10, bcl-6 but not bcl-2, with high Ki-67 index (90%) and c-MYC translocation. She was treated with Pola-R-CHP. After the first dose of therapy, her abdominal pain was rapidly relieved. A grade 3 pneumonia after the fourth cycle was treated with antibiotics and best supportive care. After 6 cycles of induction therapy, complete metabolic remission was confirmed by positron emission tomography/computed tomography (PET/CT). To consolidate the response, she underwent autologous stem cell transplantation, and afterward, complete metabolic remission status was maintained. The last CT scan showed a continuous response of 12.9 months after the initiation of chemoimmunotherapy. Follow-up was still ongoing through blood tests and CT examination every 3 months. CONCLUSIONS Upfront Pola-R-CHP had a quick and durable response and was well-tolerated in untreated Burkitt lymphoma. Further research is required to confirm the conclusions.</p>","PeriodicalId":39064,"journal":{"name":"American Journal of Case Reports","volume":"26 ","pages":"e948969"},"PeriodicalIF":0.7000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477965/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Pola-R-CHP and Autologous Stem Cell Transplantation in Untreated Burkitt Lymphoma: A Case Report.\",\"authors\":\"Yang Yang, Yuhong Ren, Jing Li, Peng Liu\",\"doi\":\"10.12659/AJCR.948969\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BACKGROUND Burkitt lymphoma is an aggressive B-cell lymphoma curable with highly dose-intensive chemotherapy derived from pediatric leukemia regimens. However, the adverse event profile, including myelosuppression, infection, and multi-organ dysfunction, worsens with increasing age. This report describes the first case of an 56-year-old woman diagnosed with Burkitt lymphoma who was treated with upfront polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) followed by autologous stem cell transplantation consolidation. CASE REPORT An 56-year-old Asian female patient with reduced body weight and severe malnutrition and unfit for standard therapies had an aggravating onset of abdominal pain and constipation. Diagnosis of high-risk Burkitt lymphoma was made by pathological biopsy, with intermediate-sized mature malignant B cells that expressed CD10, bcl-6 but not bcl-2, with high Ki-67 index (90%) and c-MYC translocation. She was treated with Pola-R-CHP. After the first dose of therapy, her abdominal pain was rapidly relieved. A grade 3 pneumonia after the fourth cycle was treated with antibiotics and best supportive care. After 6 cycles of induction therapy, complete metabolic remission was confirmed by positron emission tomography/computed tomography (PET/CT). To consolidate the response, she underwent autologous stem cell transplantation, and afterward, complete metabolic remission status was maintained. The last CT scan showed a continuous response of 12.9 months after the initiation of chemoimmunotherapy. Follow-up was still ongoing through blood tests and CT examination every 3 months. CONCLUSIONS Upfront Pola-R-CHP had a quick and durable response and was well-tolerated in untreated Burkitt lymphoma. Further research is required to confirm the conclusions.</p>\",\"PeriodicalId\":39064,\"journal\":{\"name\":\"American Journal of Case Reports\",\"volume\":\"26 \",\"pages\":\"e948969\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477965/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12659/AJCR.948969\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12659/AJCR.948969","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

伯基特淋巴瘤是一种侵袭性b细胞淋巴瘤,可通过源自儿科白血病方案的高剂量强化化疗治愈。然而,不良事件,包括骨髓抑制、感染和多器官功能障碍,随着年龄的增长而恶化。本报告描述了第一例56岁女性诊断为伯基特淋巴瘤,她接受了前期polatuzumab vedotin +利妥昔单抗、环磷酰胺、阿霉素和强的松(Pola-R-CHP)治疗,随后进行了自体干细胞移植巩固。病例报告一名56岁的亚洲女性患者,体重减轻,严重营养不良,不适合标准治疗,腹痛和便秘加重。高危伯基特淋巴瘤的诊断是病理活检,中等大小的成熟恶性B细胞表达CD10, bcl-6但不表达bcl-2, Ki-67指数高(90%),c-MYC易位。她接受了Pola-R-CHP治疗。第一次服药后,她的腹痛迅速缓解。第四个周期后的3级肺炎接受抗生素治疗和最佳支持性护理。诱导治疗6个周期后,通过正电子发射断层扫描/计算机断层扫描(PET/CT)证实代谢完全缓解。为了巩固这种反应,她接受了自体干细胞移植,之后,完全代谢缓解状态得以维持。最后一次CT扫描显示化疗免疫治疗开始后12.9个月的持续反应。随访仍在进行,每3个月进行一次血液检查和CT检查。结论:对于未经治疗的伯基特淋巴瘤,前期Pola-R-CHP具有快速、持久的反应,耐受性良好。需要进一步的研究来证实这些结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficacy of Pola-R-CHP and Autologous Stem Cell Transplantation in Untreated Burkitt Lymphoma: A Case Report.

BACKGROUND Burkitt lymphoma is an aggressive B-cell lymphoma curable with highly dose-intensive chemotherapy derived from pediatric leukemia regimens. However, the adverse event profile, including myelosuppression, infection, and multi-organ dysfunction, worsens with increasing age. This report describes the first case of an 56-year-old woman diagnosed with Burkitt lymphoma who was treated with upfront polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) followed by autologous stem cell transplantation consolidation. CASE REPORT An 56-year-old Asian female patient with reduced body weight and severe malnutrition and unfit for standard therapies had an aggravating onset of abdominal pain and constipation. Diagnosis of high-risk Burkitt lymphoma was made by pathological biopsy, with intermediate-sized mature malignant B cells that expressed CD10, bcl-6 but not bcl-2, with high Ki-67 index (90%) and c-MYC translocation. She was treated with Pola-R-CHP. After the first dose of therapy, her abdominal pain was rapidly relieved. A grade 3 pneumonia after the fourth cycle was treated with antibiotics and best supportive care. After 6 cycles of induction therapy, complete metabolic remission was confirmed by positron emission tomography/computed tomography (PET/CT). To consolidate the response, she underwent autologous stem cell transplantation, and afterward, complete metabolic remission status was maintained. The last CT scan showed a continuous response of 12.9 months after the initiation of chemoimmunotherapy. Follow-up was still ongoing through blood tests and CT examination every 3 months. CONCLUSIONS Upfront Pola-R-CHP had a quick and durable response and was well-tolerated in untreated Burkitt lymphoma. Further research is required to confirm the conclusions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American Journal of Case Reports
American Journal of Case Reports Medicine-Medicine (all)
CiteScore
1.80
自引率
0.00%
发文量
599
期刊介绍: American Journal of Case Reports is an international, peer-reviewed scientific journal that publishes single and series case reports in all medical fields. American Journal of Case Reports is issued on a continuous basis as a primary electronic journal. Print copies of a single article or a set of articles can be ordered on demand.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信